Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company

Sanofi’s Q2 2024 Results Showcase Robust Growth in Pharma and Consumer Health Divisions

Fineline Cube Jul 25, 2024

Sanofi (NASDAQ: SNY; EPA: SAN), the French multinational pharmaceutical company, has reported its financial results...

Company Deals

Agilent Technologies and Shanghai Majorbio Bio-pharm Ink Deal to Transform Life Science Research in China

Fineline Cube Jul 25, 2024

Agilent Technologies (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets,...

Company Deals

Nanjing Sanhome Pharmaceutical and China Resource Pharma Deepen Collaboration for Market Expansion

Fineline Cube Jul 25, 2024

Nanjing Sanhome Pharmaceutical Co., Ltd, a Chinese pharmaceutical company, and China Resource Pharmaceutical Commercial Group...

Company Drug

Jiangsu Suzhong Pharma’s Sutetinib Earns Breakthrough Designation for NSCLC from China’s NMPA

Fineline Cube Jul 25, 2024

Jiangsu Suzhong Pharma Group Co., Ltd, a leading pharmaceutical company based in China, has received...

Company Deals Medical Device

Edwards Lifesciences to Acquire Peijia Medical’s US Partner JenaValve, Impact on Licensing Deal Minimal

Fineline Cube Jul 25, 2024

China-based Peijia Medical Ltd (HKG: 9996) has announced that its US-based partner JenaValve Technology Inc....

Company Deals

RemeGen Scales Back Private Placement to Fund New Drug R&D

Fineline Cube Jul 25, 2024

RemeGen (HKG: 9995), a biopharmaceutical company based in China, has revised its private placement plan,...

Policy / Regulatory

China’s NMPA Suspends Daewoong Bio’s Antibiotic, Excludes Firm from National Procurement Program

Fineline Cube Jul 25, 2024

The National Medical Products Administration (NMPA) in China has taken a decisive step to suspend...

Company Drug

Hainan Poly Pharm’s Novel Nanomedicine PLAT001 Cleared for Clinical Trial by NMPA

Fineline Cube Jul 25, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...

Company Drug

Hinova Pharmaceuticals Receives NMPA Approval to Test Myelofibrosis Drug Candidate HP560

Fineline Cube Jul 25, 2024

Hinova Pharmaceuticals Inc. (SHA: 688302), a biopharmaceutical company based in Chengdu, has announced that it...

Company Drug

Belief BioMed and Takeda’s Hemophilia B Gene Therapy BBM-H901 Accepted for NMPA Review

Fineline Cube Jul 25, 2024

Belief BioMed Group (BBM), a Shanghai-based gene therapy specialist, and Takeda have announced that the...

Company Deals

Pinetree Therapeutics Strikes EGFR Degrader Deal with AstraZeneca Worth Over USD 500 Million

Fineline Cube Jul 25, 2024

Pinetree Therapeutics Inc., a Massachusetts-based biotechnology company, has announced the signing of an exclusive option...

Company Deals

Novartis Partners with Dren Bio to Develop Next-Generation Cancer Therapies

Fineline Cube Jul 25, 2024

Novartis (NYSE: NVS), a leading Swiss pharmaceutical company, has entered into a strategic collaboration with...

Company Drug

Pfizer’s Hemophilia A Gene Therapy Shows Promise in Phase III AFFINE Study

Fineline Cube Jul 25, 2024

Pfizer Inc. (NYSE: PFE), a US pharmaceutical giant, has announced positive topline results from the...

Company Drug

Novo Nordisk’s Wegovy Approved in the UK to Reduce Cardiovascular Risks in Overweight Adults

Fineline Cube Jul 24, 2024

Novo Nordisk (NYSE: NVO)’s anti-obesity drug Wegovy (semaglutide) has received a new indication approval in...

Company Drug

IASO Biotherapeutics’ CAR-T Therapy Fucaso Receives FDA IND Approval for Multiple Sclerosis

Fineline Cube Jul 24, 2024

China-based IASO Biotherapeutics has announced that it has received Investigational New Drug (IND) approval from...

Company Drug

ST Phi Therapeutics’ Universal Cell Therapy for Solid Tumors Gets Green Light for Clinical Trial in China

Fineline Cube Jul 24, 2024

ST Phi Therapeutics, a Hangzhou-based cell therapy specialist, has secured tacit approval from China’s National...

Company

Shanghai Rightongene Biotechnology Co., Ltd Executives Under Investigation by Chinese Authorities

Fineline Cube Jul 24, 2024

Shanghai Rightongene Biotechnology Co., Ltd (SHA: 688217), a Chinese biopharmaceutical company, has announced that key...

Company Medical Device

Hangzhou Jianjia Medical’s Arthbot Surgical Robot Receives NMPA Approval for Orthopedic Procedures

Fineline Cube Jul 24, 2024

Hangzhou Jianjia Medical Technology Co., Ltd has received marketing approval from China’s National Medical Products...

Company Drug

Innorna’s Herpes Zoster mRNA Vaccine IN001 Receives Clinical Trial Approval in China

Fineline Cube Jul 24, 2024

Shenzhen-based Innorna Co., Ltd has announced that it has received approval from the National Medical...

Company

BeiGene Launches Flagship US Facility in New Jersey to Expand Oncology R&D and Manufacturing

Fineline Cube Jul 24, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a global biotechnology company, has announced the inauguration...

Posts pagination

1 … 378 379 380 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.